124I-Cetuximab uptake measurements demonstrated that AT13387 significantly reduced EGFR expression in tumours with high expression and tumours with low expression by 67 % (p < 0.001) and 40 % (p < 0.05), respectively (Fig. 4a). Here, EGFR is linked to neoplasm.